Malignant Mastocytosis — Trials

Malignant Mastocytosis — Trials · CancerIndex

Clinical trials

Registered studies

14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 3
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 67%
Top sponsor: Cogent Biosciences, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–6 of 6 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03580655	(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis	completed	Phase 2	107	Blueprint Medicines CorporationINDUSTRY	12	Apr 24, 2026	clinicaltrials
NCT02571036	A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	completed	Phase 1	282	Deciphera Pharmaceuticals, LLCINDUSTRY	6	Dec 13, 2023